Endocrine Abstracts

Background: The activating somatic point mutation, BRAFV600E, is the most common genetic alteration observed in papillary thyroid carcinoma (PTC) but its oncogenic role in PTC has been extensively investigated. Numerous studies reported that BRAFV600E correlates with poor clinical outcome, whereas others have found no such association. It is estimated that BRAFV600E occurs in ~ 45–50% of PTC cases, but recent studies showed the more freque...

Introduction: Still there is a discussion about the importance of diagnostic and prognostic relevance BRAFV600E mutation. The wide range of BRAFV600E mutation frequency (40–80%) doesn’t facilitate this task. Population diversity and genotyping methodology are suspected sources of differences seen in the mutation frequencies detected by different studies. The aim of this study was to assess the prevalence BRAF V600...

Introduction: BRAFV600E mutation constitutes 98–99% of all detected mutation in thyroid carcinoma. The remaining 2% are BRAF mutations detected in the vicinity of codon V600. Due to the low incidence not much is known about their importance for the development of papillary thyroid carcinoma (PTC). In addition, some of these mutations co-occur with the mutation BRAFV600E.Methods/design: The study prese...